Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cosyntropin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 2/20 | 0.73 |
| ▸ | MC4R | P32245 | 3/20 | 0.72 |
| ▸ | MC5R | P33032 | 2/20 | 0.72 |
| ▸ | MC3R | P41968 | 2/20 | 0.72 |
| ▸ | MC1R | Q01726 | 2/20 | 0.72 |
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | CTSS | P25774 | 3/20 | 0.64 |
| ▸ | CTSK | P43235 | 3/20 | 0.64 |
| ▸ | CTSH | P09668 | 1/20 | 0.64 |
| ▸ | GLP1R | P43220 | 4/20 | 0.64 |
| ▸ | GCGR | P47871 | 3/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.60 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.59 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.59 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.59 |
| ▸ | NMBR | P28336 | 1/20 | 0.58 |
| ▸ | GRPR | P30550 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cosyntropin SCHEMBL31252906 | 1.00 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL563374 | 1.00 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL25356191 | 1.00 | C5AR1 (0.73) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL29948667 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL29383133 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL27555834 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL720535 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL33366 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL522396 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R | |
| Cosyntropin SCHEMBL16649201 | 0.99 | C5AR1 (0.74) | C5AR1MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4482481-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH S A (ES) | 2025-11-12 | — | — | EP | claimed |
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2025-05-15 | — | — | US | claimed |
| EP-4482481-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | Som Innovation Biotech, S.L. (ES) | 2025-01-01 | — | — | EP | claimed |
| WO-2023156645-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH, S.A. (ES) | 2023-08-24 | — | — | WO | claimed |
| EP-4230196-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | Som Innovation Biotech, S.A. (ES) | 2023-08-23 | — | — | EP | claimed |
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | claimed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | claimed |
| EP-1878454-B1 | Antihemorrhagic treatment kit | HEALTH RICERCA E SVILUPPO S R L (IT) | 2019-04-24 | — | — | EP | claimed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | claimed |
| WO-2017223085-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | claimed |
| US-20150110885-A1 | PARENTERAL PHARMACEUTICAL COMPOSITION CONTAINING COSYNTROPIN | EMS S/A (BR) | 2015-04-23 | — | — | US | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250375388-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | UNIV MICHIGAN REGENTS (US) | 2025-12-11 | — | — | US | disclosed |
| EP-4482481-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | SOM INNOVATION BIOTECH S A (ES) | 2025-11-12 | — | — | EP | disclosed |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-07-03 | — | — | US | disclosed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | disclosed |
| WO-2017223085-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | disclosed |
| WO-2016138436-A2 | ADRENOCORTICOTROPIC HORMONE ANALOGUE FORMULATIONS | Retrophin, Inc. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20150110885-A1 | PARENTERAL PHARMACEUTICAL COMPOSITION CONTAINING COSYNTROPIN | EMS S/A (BR) | 2015-04-23 | — | — | US | disclosed |
| EP-2862578-A1 | Parenteral pharmaceutical composition containing cosyntropin | EMS S.A. (BR) | 2015-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250152567-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES | MTPN, UTRN, TTN | C5AR1 4672/4885MC4R 4149/4885MC5R 4273/4885 |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | C5AR1 67/4885MC4R 3054/4885MC5R 2775/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | C5AR1 1518/4885MC4R 2222/4885MC5R 2514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.